Umoja Biopharma, Inc. – Trademark Portfolio
Entity Type: 03
Umoja Biopharma, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 6 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include U, RACR, UMOJA, and VIVOVEC. The owner is based in Seattle, WA.
1150 Eastlake Ave E, Suite 400
Seattle, WA 98109
Showing of trademarks Trademarks
Trademark Classifications
Umoja Biopharma, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Umoja Biopharma, Inc. have?
Umoja Biopharma, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 abandoned.
What trademark classes does Umoja Biopharma, Inc. file in?
Umoja Biopharma, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Umoja Biopharma, Inc.'s most well-known trademarks?
Umoja Biopharma, Inc.'s registered trademark portfolio includes well-known marks such as U, RACR, UMOJA, and VIVOVEC. These are among 4 currently registered trademarks in the portfolio.
What is Umoja Biopharma, Inc.'s trademark registration success rate?
Umoja Biopharma, Inc. has a 67% trademark registration rate, with 4 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.